



HHS Public Access

Author manuscript

Mucosal Immunol. Author manuscript; available in PMC 2021 January 10.

Published in final edited form as:

Mucosal Immunol. 2021 January ; 14(1): 144–151. doi:10.1038/s41385-020-0308-4.

Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation

Katharina Maisel¹, Cara L. Hrusch², Jorge E. G. Medellin¹, Lambert Potin¹, David B. Chapel³, Harri Nurmi⁴, Daniel F. Camacho², Rachel Gleyzer¹, Kari Alitalo⁴, Anne I. Sperling^{2, #}, Melody A. Swartz^{1, 5, #}

¹Institute for Molecular Engineering, University of Chicago, Chicago, IL USA ²Department of Medicine, Section of Pulmonary and Critical Care Medicine, and the Committee on Immunology, University of Chicago, Chicago, IL USA ³Department of Pathology, University of Chicago, Chicago, IL USA ⁴Wihuri Research Institute and Translational Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland ⁵Ben May Institute for Cancer Research, University of Chicago, Chicago, IL USA

Abstract

In allergic airway inflammation, VEGFR-3-mediated lymphangiogenesis occurs in humans and mouse models, yet its immunological roles, particularly in adaptive immunity, are poorly understood. Here, we explored how pro-lymphangiogenic signaling affects the allergic response to house dust mite (HDM). In the acute inflammatory phase, the lungs of mice treated with blocking antibodies against VEGFR-3 (mF4-31C1) displayed less inflammation overall, with dramatically reduced innate and T cell numbers and reduced inflammatory chemokine levels. However, when inflammation was allowed to resolve and memory recall was induced 2 months later, mice treated with mF4-31C1 as well as VEGF-C/-D knockout models showed exacerbated type 2 memory response to HDM, with increased Th2 cells, eosinophils, type 2 chemokines, and pathological inflammation scores. This was associated with lower CCL21 and decreased T_{Reg}s in the lymph nodes. Together, our data imply that VEGFR-3 activation in allergic airways both help initiate the acute inflammatory response as well as regulate the adaptive (memory) response, possibly in part by shifting the T_{Reg}/Th2 balance. This introduces new immunomodulatory roles for pro-lymphangiogenic VEGFR-3 signaling in allergic airway inflammation and suggests that airway lymphatics may be a novel target for treating allergic responses.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

#Correspondence should be addressed to: Melody Swartz, PhD, Department of Molecular Engineering, University of Chicago, melodyswartz@uchicago.edu, OR, **Anne Sperling, PhD**, Department of Medicine, Section of Pulmonary and Critical Care Medicine, and the Committee on Immunology, University of Chicago, asperlin@medicine.bsd.uchicago.edu.

Author contributions:

KM designed, performed, and analyzed experiments and wrote the manuscript. CLH, DFC, and LP aided in experimental design, analysis, data interpretation, and manuscript preparation. DBC performed histological analysis, and JEGM, HN, and RG aided in experiments and data collection. KA, AIS, and MAS helped design experiments, interpreted data, and edited the manuscript.

The authors declare no conflicts of interest.

Keywords

Asthma; VEGF-C; VEGF-D; acute; resolution

INTRODUCTION

Allergic asthma is a chronic inflammatory disease that is characterized by airway hyper-responsiveness, enhanced mucus production, type 2 immune cell infiltration, and smooth muscle contraction, all in response to inhalation of a specific allergen such as cat dander or house dust mite (HDM). Sensitization to the allergen involves the activation of type 2 CD4⁺ (Th2) T cells and IgE-producing B cells, which in turn activate and recruit eosinophils, mast cells (in humans), and macrophages; other cellular modulators include Th17, Th9, and regulatory (T_{Reg}) CD4⁺ T cells as well as type 2 innate lymphoid cells (ILC2)¹⁻³. Lymphatic vessels, which transport antigens, cytokines, and immune cells to the lymph nodes (LN), are critical to both the clearance of inflammatory cells and the induction and regulation of adaptive immune responses^{4,5}. Lymphatic expansion or lymphangiogenesis, driven by vascular endothelial growth factor (VEGF) receptor 3 (VEGFR-3) signaling by its ligands VEGF-C and/or VEGF-D, occurs in allergic airway disease, particularly near bronchi and arteries^{6,7}, although its pathological consequences are poorly understood^{8,9}.

While lymphangiogenesis has been reported to occur in numerous types of chronic inflammatory diseases, including cancer, inflammatory bowel disease (IBD), chronic respiratory infection, and chronic skin inflammation, we still lack an integrated comprehension of how it alters adaptive immune responses in such diseases. In cancer, lymphangiogenesis plays complex roles in shaping the immune response^{4,5,10,11}, both promoting immune suppression as well as, paradoxically, priming adaptive immune responses¹². In mouse models of chronic inflammatory arthritis and inflammatory bowel disease, blocking VEGFR-3 signaling was found to exacerbate inflammation¹³⁻¹⁵, but in Crohn's disease patients, excessively dilated and obstructed lymphatic vessels have been associated with lymph stasis, suggesting that blocking lymphangiogenesis should reduce inflammation¹⁶. In oxazolone-induced chronic skin inflammation, VEGFR-3 stimulation is protective, hampering the development of epidermal hyperplasia and accumulation of CD8⁺ T cells^{17,18}. In corneal, cardiac, and islet transplantation studies in mice, VEGFR-3 stimulation is promotes graft rejection¹⁹⁻²¹.

In non-allergy models of chronic lung inflammation, such as chronic respiratory infection of *Mycoplasma pulmonis*, lymphangiogenesis has been shown to play protective roles by promoting lymphatic drainage and resolution of inflammation²²⁻²⁴. However, those studies used inflammatory mediators that induce type 1 inflammation, such as mismatched transplantation²⁴ or bacterial infection^{22,23}. Much less is known about lymphangiogenesis in chronic type 2 inflammatory diseases. Interestingly, Th2 cytokines, particularly IL-4 and IL-13, have been reported to *inhibit* lymphangiogenesis^{25,26}, which appears inconsistent to reports of lymphangiogenesis in allergic airway disease^{6,7}.

Here, we asked whether pro-lymphangiogenic signaling plays protective or pathogenic roles in allergic airway inflammation, focusing on the adaptive immune response to with memory

recall challenges. Using both blocking antibodies against VEGFR-3 and transgenic models, we show that VEGFR-3 signaling facilitates the acute inflammatory response to HDM, but is protective with respect to memory challenges. This work highlights the complexity of pro-lymphangiogenic VEGFR-3 signaling in regulating both innate and adaptive immunity in allergic airway disease.

RESULTS

Lymphangiogenesis occurs late after the onset of allergic airway inflammation

To explore the roles of lymphangiogenesis and VEGFR-3 signaling in a murine model of HDM-mediated allergic airway inflammation, we developed a long-term model (Fig. 1A) that allowed us to study the acute inflammatory peak (day 13)²⁷, resolution (day 31), and memory recall response (day 69), as evidenced by the characteristic changes in eosinophilia and Th2 cells (Fig. 1B). Cell numbers were determined by flow cytometry (gating strategies in Suppl. Fig. 1A–C). In this model, we found that VEGF-C was significantly increased in the resolution phase at day 31 (Fig. 1C). Histopathological features of airway inflammation were seen at day 13 and after memory recall at day 69 (Fig. 1D). Lymphatic vessels, immunostained for VEGFR-3 (a common marker of lung lymphatics^{22,23}), were increased in density at day 31 compared to PBS-treated mice (Fig. 1E–F), although LECs began to express the cell proliferation marker Ki-67 by day 11 (Suppl. Fig. 1C–D). We could prevent lymphatic vessel expansion with systemic administration of mF4-31C1 (Fig. 1F), a blocking antibody against mouse VEGFR-3 that prevents lymphangiogenesis without affecting existing lymphatics²⁸.

Blocking VEGFR-3 signaling reduces overall CD45+ cells during acute allergic inflammation and modulates dLN cellular composition during acute inflammation and resolution

Having established that lymphangiogenesis occurs in the resolution phase, we sought to understand how blocking pro-lymphangiogenic VEGFR-3 signaling modulates the acute response and resolution in allergic airway inflammation. We blocked VEGFR-3 using mF4-31C1 throughout the entire experiment for the acute schedule and until day 21 for the resolution schedule (Fig. 2A). We found that VEGFR-3 blockade significantly decreased many inflammatory (CD45⁺) cell populations present in lung tissues at day 13, including eosinophils, T cells, B cells, monocytes, and neutrophils (Fig. 2B top, 2C), but not alveolar macrophages (Suppl. Fig. 2A). Blocking VEGFR-3 reduced these cell types similarly relative to the total CD45⁺ population (Fig. 2C, Suppl. Fig. 2A). During resolution at day 31, these were decreased below baseline levels in both the control and mF4-31C1 treated mice (Fig. 2B bottom); however, relative to all CD45⁺ cells in the lung, both neutrophil and eosinophil populations were reduced more in mice treated with mF4-31C1 compared to controls upon post-inflammatory cascade contraction (Fig. 2C). When we looked more specifically at the CD4⁺ T cell subsets, we found that at day 13 in the lungs both T_{Reg} cells and naïve CD4⁺ T cells (T_{naïve}) were slightly decreased, though not significant, in mF4-31C1 treated mice. We also found that IL-4 and IL-10, but not IL-5 producing CD4⁺ T cells restimulated in vitro with HDM were decreased in lungs of mF4-31C1 treated mice (Suppl. Fig. 2B). At day 31, the lung subsets are unchanged (Fig. 2D).

While in the lungs no significant changes in CD4⁺ T cell subsets were found, CD4⁺ T cell subsets in the dLN are significantly affected by mF4-31C1 treatment at both time points: CD4⁺ T_{naïve} are increased, while T_{Reg} cells are decreased (Fig. 3A). Th2 cells are only decreased at day 13 (Fig. 3A), consistent with overall decreased inflammation in the lungs upon mF4-31C1 treatment, but are unchanged at day 31 (Fig. 3A). Naïve T cells are known to express CCR7, the receptor for the chemokine CCL21. It has been established that lymphatics, particularly during inflammation and in response to pro-lymphangiogenic VEGF-C, produce CCL21^{4,5,29}. CCL21 is present at steady state in both lungs and dLNs (lungGENs database)^{30,32}. Since VEGFR-3 signaling induces CCL21 upregulation in LECs and we observed changes in the CCR7⁺ T cell compartment, we sought to analyze CCL21 levels in the lungs upon VEGFR-3 blocking. At day 13, mF4-31C1 treatment decreased CCL21 in the lungs, quantified by immunofluorescence and ELISA (Fig. 3B–C). In the dLNs, however, CCL21 levels did not decrease with mF4-31C1 treatment at day 13 (Fig. 3C). In our experiments, we observed proportional decreases of several innate cells along with T cells, including neutrophils and monocytes (both were decreased in total number upon mF4-31C1 treatment), which are not known to express CCR7. We therefore sought to assess changes in other chemokines due to mF4-31C1 treatment. Using a multiplex kit (luminex), we found that several other chemokines, including CXCL2, CCL5, CCL7, CXCL10, CCL11, CCL12, CCL2, CXCL13, CCL3, and CXCL12 are also decreased by mF4-31C1 treatment (Fig. 3D).

Blocking VEGFR-3 signaling exacerbates the memory response to HDM

We sought to assess changes in the memory response when performing mF4-31C1 treatment during the first 21 days of the allergic response (Fig. 4A) and re-challenging with HDM after several weeks. We found that overall lung inflammation, as indicated by CD45⁺ cell numbers (Fig 4B), including total T cells and CD4⁺ T cells (Suppl. Fig. 3A), as well as histologically (Fig. 4C), were not enhanced in mice receiving mF4-31C1 treatment. However, we found an increase in eosinophils (Fig. 4D, Suppl. Fig. 3B), CD4⁺ Th2s (Fig 4D), and CD4⁺ T_{EM} (Suppl. Fig. 3C), but not T_{Reg} cells (Fig. 4D) or serum IgE levels (Suppl. Fig. 3D). Furthermore, both the ratios of CD4⁺ T_{EM} to T_{CM} and Th2 to T_{Reg} are increased in mF4-31C1 vs. isotype antibody (IgG) treated mice (Fig. 4E). Additionally, *in vitro* restimulation with PMA and ionomycin clearly showed enhanced levels of IL-4⁺, IL-13⁺, and IL-4⁺ IL-13⁺ double positive CD4⁺ T cells (Fig. 4F, Suppl. Fig. 3E), but not IFN γ ⁺ CD4⁺ T cells in mF4-31C1 treated mice. Overall type 2 cytokine producing cells made up ~50% of CD4⁺ T cells in mF4-31C1 treated mice, compared to ~30% in mice receiving isotype antibody treatment (Fig. 4F). HDM specific restimulation of T cells showed increased IL-5 and IL-13, though not significant ($0.05 < p < 0.1$), but not IFN γ (Fig. 4G).

Mice lacking VEGF-C and VEGF-D show exacerbated memory response to HDM.

To understand if the exacerbated memory response is dependent on the absence of one of, or both, pro-lymphangiogenic growth factors (i.e. VEGF-C and/or VEGF-D), we compared the memory response induced by HDM in wild type ('WT') mice with that in mice lacking either VEGF-C (*Rosa26^{Cre}-ERT2; Vegfc^{flox/flox}*, herein referred to as 'VEGF-C KO' or 'VC KO' in Figures), VEGF-D (*Vegfd^{-/-}*, herein referred to as 'VEGF-D KO' or 'VD KO' in

Figures), or both (*Rosa26*^{Cre-ERT2}; *Vegfc*^{flox/flox}; *Vegfd*^{-/-}, herein referred to as ‘double KO’) that have been previously described^{33,34}. We induced *Vegf-c* deletion prior to HDM challenge in our established memory schedule (Fig. 5A), and then assessed the histopathology of the lungs (Fig. 5B). After blinded scoring, we found that inflammation surrounding both vessels and airways was enhanced from 3 ± 1 around vessels and 2 ± 1 around airways in WT mice to 5 ± 1 (vessels) and 4 ± 1 (airways) in double KO mice (Fig. 5C, scoring criteria can be found in the Supplementary Methods Section). It also appears that lack of VEGF-D alone results in these pathological changes (Fig. 5C).

We next sought to assess differential inflammatory cell infiltration into the lungs in these mice (Fig. 5D–G). With HDM treatment, lungs of double KO mice contained slightly increased eosinophils (though not significant, Fig. 5D), increased CD4⁺ T_{EM}/T_{CM} ratios (Fig. 5E), increased Th2 CD4⁺ T cells (Fig. 5F), and higher ratios of Th2/T_{Reg} cells (Fig. 5G). No inflammation was induced by removing VEGF-C and/or VEGF-D in control PBS treated mice (Fig. 5D, F). When we examined the functionality of these cells by restimulating *in vitro* with PMA and ionomycin, we found a 2.8 - fold increase in both IL-5⁺ and IL-13⁺, but not IFN γ ⁺ CD4⁺ T cells (Fig. 5H–I). This effect appeared to be antigen specific, as HDM restimulation of lung single cell suspension resulted in enhanced IL-4, IL-5, and IL-13 but not IFN γ levels produced by lung cells (Fig. 5J).

DISCUSSION

In our presented work, we have found that pro-lymphangiogenic VEGFR-3 signaling modulates allergic airway inflammation. During acute inflammation, VEGFR-3 blocking decreased immune cell recruitment into the lungs, though more naïve T cells were found in the dLN. In contrast, the memory response to allergen is significantly exacerbated by a lack of VEGFR-3 signaling (either by mF4-31C1 treatment or in mice lacking VEGF-C and/or VEGF-D). We found that the exacerbated memory response is dependent on the absence of both VEGF-C and VEGF-D, suggesting that these two growth factors may compensate for each other in allergic airway inflammation. We hypothesize that the changes in the memory response may at least in part be due to the decrease of CCL21 levels in the lungs (but not in the dLN) at day 13 that cause accumulation of naïve T cells in the dLN, leading to more priming of the increased naïve T cells. Increased T cell priming could ultimately lead to the exacerbated memory response we find at D69. We suspect that effects of blocking pro-lymphangiogenic VEGFR-3 signaling were both due to altering lung lymphatics, and by affecting immune cells such as macrophages that may also respond to VEGFR-3 stimulation. Taken together, our work is the first study to describe critical roles of pro-lymphangiogenic signaling in modulating immunity during allergic airway inflammation: leading to enhanced acute inflammation but an ameliorated memory response later on.

Existing studies on allergic inflammation and lymphangiogenesis generally focused on whether or not lymphangiogenesis occurs, and have led to conflicting findings^{6,9,25,35,36}. Our findings corroborate studies showing lymphangiogenesis in a HDM model of respiratory allergies in rats⁶, and studies by Kretschmer et al demonstrating that house dust mite challenge leads to lymphangiogenesis and T cell infiltration in murine lungs³⁷. Other studies have also demonstrated that lymphangiogenesis occurs more broadly in chronic

airway inflammation, particularly during diseases such as lymphangioliomyomatosis, and in certain regions within lungs of idiopathic pulmonary fibrosis patients^{7,22,23,37–40}. Interestingly, fatal asthma in humans, where fibrosis has occurred in much of the lung, is associated with fewer lymphatic vessels in the lungs^{9,25,35}. However, a thorough study of how lymphatic vessels are altered during disease progression in human asthmatic patients has yet to be performed, and existing studies in mice and rats likely are more representative of earlier time points than fatal asthma.

The CCL21/CCR7 axis is a well-established mechanism by which lymphatics modulate immunity, and CCL21 production can be induced in LECs with VEGF-C. In the dLNs, lymphatics are one of the major sources of CCL21, which attracts CCR7⁺ T cells and DCs^{29,41}. Previous studies by Baluk et al demonstrated that CCL21 is increased in mouse lung lymphatics during chronic bacterial infections²³. Here, we have found that CCL21 is reduced in the lungs during acute inflammation when pro-lymphangiogenic signaling is blocked. This axis has also been studied in allergic airway inflammation using *Ccr7*^{-/-} knockout mice or mice lacking CCL21/CCL19 expression in secondary lymphoid organs (*plt/plt* mice)^{30,31}. Kawakami et al showed that *Ccr7*^{-/-} KO mice have an exacerbated response to HDM, with increased eosinophilia, IL-13 levels in the lungs, and airway response to acetylcholine³⁰. In contrast, Ploix et al demonstrated that *plt/plt* mice did not appear to have significantly changed responses to an OVA/alum based model of allergic airway inflammation³¹. Another study by Xu et al with *plt/plt* mice appears to contradict this, clearly demonstrating greater eosinophilia and lymphocyte numbers in the bronchoalveolar lavage fluid (BAL), inflammation score of lung histology, type 2 cytokines (as detected by RNA), and IgE production in *plt/plt* mice compared to controls⁴². A third study by Yamashita et al suggests that early on, airway inflammation was reduced in *plt/plt* mice, as indicated by airway response to acetylcholine and overall lymphocytes and cell numbers in BAL⁴³. However, after cessation of antigen dosing, inflammation appears to resolve less in *plt/plt* mice compared to wild type controls, reconciling the earlier studies⁴³. Similarly, our data demonstrate that overall inflammatory cell numbers are decreased early on, though allergic inflammation is still present, and a robust memory response is formed. Differences between our results and those from *plt/plt* mice likely stem from the fact that in *plt/plt* mice, CCL21 is still produced at low levels in LECs, which may have been increased during inflammation, a possibility that was not considered in the discussed studies. In addition, both CCL21 and CCL19 are abrogated entirely from the dLNs in *plt/plt* mice, whereas our studies likely affected mostly the LEC population. This is substantiated by previous studies showing that VEGFR-3 blocking abrogates CCL21 production mainly in LECs, but may not modulate CCL21 production in other cell types^{20,44,45}. Additionally, we found that VEGFR-3 blocking not only modulated CCL21, but also decreased other chemokines involved in recruitment of immune cells including T cells, eosinophils, neutrophils, and basophils, which could explain changes in non-CCR7⁺ inflammatory cells we have observed. Furthermore, other cells, including macrophages and ILCs, have been shown to express VEGFR-3 and produce chemokines, and thus may be responsible for some of the changes in chemokines and thus inflammatory cells we have observed (see Immgen database^{46–49}). It is therefore likely that VEGFR-3 blocking modulates other chemokine secretion by other immune cells during the allergic response.

Interestingly, LECs have been shown to produce several cytokines. This includes IL-7 in response to viral infection and IL-15 in response to lipopolysaccharide induced inflammation^{50,51}. IL-7 and IL-15 production suggests a role for lymphatics in the maintenance of T cell homeostasis (by IL-7)⁵² and memory, as well as homeostasis of NK cells and NK T cells (by IL-15)⁵³. Interestingly, in a model of allergic airway inflammation that specifically induces bronchus-associated lymphoid tissues by adoptive transfer of activated Th2 cells from DO11.10 OVA-specific Tg mice, Thy1⁺ LECs were shown to produce IL-7³⁶. The authors postulate that this enhances local survival of the memory Th2 population in the lungs, suggesting a critical role for LECs in immune memory maintenance³⁶. Interestingly, we have also seen that chronic allergic airway inflammation enhances IL-7 production in lung LECs (data not shown), and studies on whether VEGFR-3 signaling is critical in inducing memory T cell-maintaining phenotype in LECs during chronic HDM mediated allergic inflammation are currently ongoing.

In summary, we have found that pro-lymphangiogenic signaling exacerbates allergic memory responses. This is likely in part due to an increase in naïve T cells in the dLN, and chemokine levels in the lungs. Therefore, our studies provide new evidence that pro-lymphangiogenic signaling modulates the allergic response by first reducing inflammatory cells in the acute phase and then exacerbating memory responses.

METHODS

We induced HDM mediated allergic airway inflammation in mice. To test the effects of pro-lymphangiogenic signaling, mice were treated with VEGFR-3 antibody (mF4-31C1) blockade and lung and lymph node inflammatory cell infiltration and lymphatics were assessed using flow cytometry, in vitro restimulation, fluorescence immunostaining, and histology, and cytokine and chemokine levels were assessed using ELISA and multiplex assays. More extensive methods can be found in the Supplementary Materials.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments:

We are grateful to Yue Wang (University of Chicago) and Shentong Fang (University of Helsinki) for technical assistance, the flow cytometry core facilities at the University of Helsinki and University of Chicago, and the Human Tissue Resources Center at the University of Chicago. We also thank Bronek Pytowski (Eli Lilly) for providing the anti-VEGFR-3 blocking antibody (mF4-31C1). This work was funded by the NIAID and NHLBI (R21 AI130821 to MAS and AIS, T32 HL007605 and F32 HL134251 to KM, F30 HL137309 and T32 GM007281 to DFC) and Fonds Pierre-François Vittone (to LP). The University of Chicago Core facilities are supported by P30 CA01459.

Abbreviations:

VEGFR-3	vascular endothelial growth factor receptor 3
VEGF-C/D	vascular endothelial growth factor C/D
Th2 cells	type 2 CD4 + T cells

T_{Reg}	regulatory T cells
HDM	house dust mite
LN	lymph node
dLN	draining lymph node
ILC	innate lymphoid cells
LECs	lymphatic endothelial cells
OVA	ovalbumin
PD-L1	programmed death ligand 1
T_{naïve}	naïve CD4 T cells
WT	wild type mice
VC KO	<i>Rosa26</i> ^{Cre-ERT2} <i>Vegfc</i> ^{flox/flox} mice
VD KO	<i>Vegfd</i> ^{-/-} mice
double KO mice	<i>Rosa26</i> ^{Cre-ERT2} <i>Vegfc</i> ^{flox/flox} <i>Vegfd</i> ^{-/-}
T_{EM}	effector memory T cells
T_{CM}	central memory T cells
BAL	bronchoalveolar lavage

References

- Holtzman MJ Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. *J Clin Invest* 122, 2741–2748, doi:10.1172/JCI60325 (2012). [PubMed: 22850884]
- Fahy JV Type 2 inflammation in asthma—present in most, absent in many. *Nat Rev Immunol* 15, 57–65, doi:10.1038/nri3786 (2015). [PubMed: 25534623]
- Martinez-Gonzalez I, Steer CA & Takei F Lung ILC2s link innate and adaptive responses in allergic inflammation. *Trends Immunol* 36, 189–195, doi:10.1016/j.it.2015.01.005 (2015). [PubMed: 25704560]
- Card CM, Yu SS & Swartz MA Emerging roles of lymphatic endothelium in regulating adaptive immunity. *Journal of Clinical Investigation* 124, 943–952, doi:10.1172/jc173316 (2014).
- Maisel K, Sasso MS, Potin L & Swartz MA Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges. *Adv Drug Deliv Rev* 114, 43–59, doi:10.1016/j.addr.2017.07.005 (2017). [PubMed: 28694027]
- Moldobaeva A, Jenkins J, Zhong Q & Wagner EM Lymphangiogenesis in rat asthma model. *Angiogenesis* 20, 73–84, doi:10.1007/s10456-016-9529-2 (2017). [PubMed: 27787629]
- Detoraki A et al. Angiogenesis and lymphangiogenesis in bronchial asthma. *Allergy* 65, 946–958, doi:10.1111/j.1398-9995.2010.02372.x (2010). [PubMed: 20415716]
- Zraggen S, Ochsenbein AM & Detmar M An important role of blood and lymphatic vessels in inflammation and allergy. *J Allergy (Cairo)* 2013, 672381, doi:10.1155/2013/672381 (2013). [PubMed: 23431319]

9. Stump B, Cui Y, Kidambi P, Lamattina AM & El-Chemaly S Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung? *Am J Respir Cell Mol Biol* 57, 272–279, doi:10.1165/rcmb.2016-0290TR (2017). [PubMed: 28443685]
10. Lund AW et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. *The Journal of clinical investigation* 126, 3389–3402, doi:10.1172/JCI79434 (2016). [PubMed: 27525437]
11. Tammela T & Alitalo K Lymphangiogenesis: Molecular mechanisms and future promise. *Cell* 140, 460–476, doi:10.1016/j.cell.2010.01.045 (2010). [PubMed: 20178740]
12. Lund AW et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. *Cell reports* 1, 191–199, doi:10.1016/j.celrep.2012.01.005 (2012). [PubMed: 22832193]
13. Guo R et al. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. *Arthritis Rheum* 60, 2666–2676, doi:10.1002/art.24764 (2009). [PubMed: 19714652]
14. D'Alessio S et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. *J Clin Invest* 124, 3863–3878, doi:10.1172/JCI72189 (2014). [PubMed: 25105363]
15. Jurisic G, Sundberg JP & Detmar M Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. *Inflamm Bowel Dis* 19, 1983–1989, doi:10.1097/MIB.0b013e31829292f7 (2013). [PubMed: 23835443]
16. Liao S & von der Weid PY Inflammation-induced lymphangiogenesis and lymphatic dysfunction. *Angiogenesis* 17, 325–334, doi:10.1007/s10456-014-9416-7 (2014). [PubMed: 24449090]
17. Huggenberger R et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. *J Exp Med* 207, 2255–2269, doi:10.1084/jem.20100559 (2010). [PubMed: 20837699]
18. Huggenberger R et al. An important role of lymphatic vessel activation in limiting acute inflammation. *Blood* 117, 4667–4678, doi:10.1182/blood-2010-10-316356 (2011). [PubMed: 21364190]
19. Chen L et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. *Nat Med* 10, 813–815, doi:10.1038/nm1078 (2004). [PubMed: 15235599]
20. Nykanen AI et al. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. *Circulation* 121, 1413–1422, doi:10.1161/CIRCULATIONAHA.109.910703 (2010). [PubMed: 20231530]
21. Yin N et al. Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. *Transplantation* 92, 25–30, doi:10.1097/TP.0b013e31821d2661 (2011). [PubMed: 21508896]
22. Baluk P et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. *J Clin Invest* 115, 247–257, doi:10.1172/JCI22037 (2005). [PubMed: 15668734]
23. Baluk P et al. Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation. *Am J Pathol* 184, 1577–1592, doi:10.1016/j.ajpath.2014.01.021 (2014). [PubMed: 24631179]
24. Krebs R et al. Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. *Am J Pathol* 181, 1607–1620, doi:10.1016/j.ajpath.2012.07.021 (2012). [PubMed: 22959907]
25. Shin K et al. TH2 cells and their cytokines regulate formation and function of lymphatic vessels. *Nat Commun* 6, 6196, doi:10.1038/ncomms7196 (2015). [PubMed: 25648335]
26. Savetsky IL et al. Th2 cytokines inhibit lymphangiogenesis. *PLoS One* 10, e0126908, doi:10.1371/journal.pone.0126908 (2015). [PubMed: 26039103]
27. Williams JW et al. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. *Nat Commun* 4, 2990, doi:10.1038/ncomms3990 (2013). [PubMed: 24356538]
28. Pytowski B et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. *J Natl Cancer Inst* 97, 14–21, doi:10.1093/jnci/dji003 (2005). [PubMed: 15632376]

29. Russo E et al. Intralymphatic CCL21 Promotes Tissue Egress of Dendritic Cells through Afferent Lymphatic Vessels. *Cell Rep* 14, 1723–1734, doi:10.1016/j.celrep.2016.01.048 (2016). [PubMed: 26876174]
30. Kawakami M et al. The role of CCR7 in allergic airway inflammation induced by house dust mite exposure. *Cell Immunol* 275, 24–32, doi:10.1016/j.cellimm.2012.03.009 (2012). [PubMed: 22521241]
31. Ploix C, Zuberi RI, Liu FT, Carson MJ & Lo DD Induction and effector phase of allergic lung inflammation is independent of CCL21/CCL19 and LT-beta. *Int J Med Sci* 6, 85–92 (2009). [PubMed: 19277254]
32. Du Y, Guo M, Whitsett JA & Xu Y ‘LungGENS’: a web-based tool for mapping single-cell gene expression in the developing lung. *Thorax* 70, 1092–1094, doi:10.1136/thoraxjnl-2015-207035 (2015). [PubMed: 26130332]
33. Nurmi H et al. VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption. *EMBO molecular medicine* 7, 1418–1425, doi:10.15252/emmm.201505731 (2015). [PubMed: 26459520]
34. Baldwin ME et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. *Mol Cell Biol* 25, 2441–2449, doi:10.1128/MCB.25.6.2441-2449.2005 (2005). [PubMed: 15743836]
35. Ebina M Remodeling of airway walls in fatal asthmatics decreases lymphatic distribution; beyond thickening of airway smooth muscle layers. *Allergol Int* 57, 165–174, doi:10.2332/allergolint.O-07-497 (2008). [PubMed: 18349592]
36. Shinoda K et al. Thy1+IL-7+ lymphatic endothelial cells in iBALT provide a survival niche for memory T-helper cells in allergic airway inflammation. *Proceedings of National Academy of Sciences USA* 113, E2842–2851, doi:10.1073/pnas.1512600113 (2016).
37. Kretschmer S et al. Visualization of intrapulmonary lymph vessels in healthy and inflamed murine lung using CD90/Thy-1 as a marker. *PLoS One* 8, e55201, doi:10.1371/journal.pone.0055201 (2013). [PubMed: 23408960]
38. Kumasaka T et al. Lymphangiogenesis in lymphangiioleiomyomatosis: its implication in the progression of lymphangiioleiomyomatosis. *The American journal of surgical pathology* 28, 1007–1016 (2004). [PubMed: 15252306]
39. Glasgow CG et al. Involvement of lymphatics in lymphangiioleiomyomatosis. *Lymphatic research and biology* 7, 221–228, doi:10.1089/lrb.2009.0017 (2009). [PubMed: 20143921]
40. Bailey E et al. Pulmonary Vasculopathy Associated with FIGF Gene Mutation. *Am J Pathol* 187, 25–32, doi:10.1016/j.ajpath.2016.09.008 (2017). [PubMed: 27846380]
41. Christopherson KW 2nd, Hood AF, Travers JB, Ramsey H & Hromas RA Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. *Blood* 101, 801–806 (2003). [PubMed: 12393410]
42. Xu B et al. Lack of lymphoid chemokines CCL19 and CCL21 enhances allergic airway inflammation in mice. *Int Immunol* 19, 775–784, doi:10.1093/intimm/dxm046 (2007). [PubMed: 17513879]
43. Yamashita N et al. Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model. *J Allergy Clin Immunol* 117, 1040–1046, doi:10.1016/j.jaci.2006.01.009 (2006). [PubMed: 16675330]
44. Goldman J et al. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. *FASEB J* 21, 1003–1012, doi:10.1096/fj.06-6656com (2007). [PubMed: 17210781]
45. Issa A, Le TX, Shoushtari AN, Shields JD & Swartz MA Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. *Cancer Res* 69, 349–357, doi:10.1158/0008-5472.CAN-08-1875 (2009). [PubMed: 19118020]
46. Shin YJ, Riew TR, Park JH, Pak HJ & Lee MY Expression of vascular endothelial growth factor-C (VEGF-C) and its receptor (VEGFR-3) in the glial reaction elicited by human mesenchymal stem cell engraftment in the normal rat brain. *J Histochem Cytochem* 63, 170–180, doi:10.1369/0022155414564218 (2015). [PubMed: 25473093]

47. Hamrah P, Chen L, Zhang Q & Dana MR Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. *Am J Pathol* 163, 57–68, doi:10.1016/S0002-9440(10)63630-9 (2003). [PubMed: 12819011]
48. Alishekevitz D et al. Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3. *Cell Rep* 17, 1344–1356, doi:10.1016/j.celrep.2016.09.083 (2016). [PubMed: 27783948]
49. Malhotra D et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. *Nat Immunol* 13, 499–510, doi:10.1038/ni.2262 (2012). [PubMed: 22466668]
50. Hara T et al. Identification of IL-7-producing cells in primary and secondary lymphoid organs using IL-7-GFP knock-in mice. *J Immunol* 189, 1577–1584, doi:10.4049/jimmunol.1200586 (2012). [PubMed: 22786774]
51. Miller CN et al. IL-7 production in murine lymphatic endothelial cells and induction in the setting of peripheral lymphopenia. *International Immunology* 25, 471–483, doi:10.1093/intimm/dxt012 (2013). [PubMed: 23657000]
52. Onder L et al. IL-7-producing stromal cells are critical for lymph node remodeling. *Blood* 120, 4675–4683, doi:10.1182/blood-2012-03-416859 (2012). [PubMed: 22955921]
53. Cui G et al. Characterization of the IL-15 niche in primary and secondary lymphoid organs in vivo. *Proc Natl Acad Sci U S A* 111, 1915–1920, doi:10.1073/pnas.1318281111 (2014). [PubMed: 24449915]
54. Tjota MY et al. IL-33-dependent induction of allergic lung inflammation by Fc γ RIII signaling. *J Clin Invest* 123, 2287–2297, doi:10.1172/JCI63802 (2013). [PubMed: 23585480]
55. Fankhauser M et al. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. *Science translational medicine* 9, doi:10.1126/scitranslmed.aal4712 (2017).
56. Lund AW et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. *The Journal of clinical investigation* 126, 3389–3402, doi:10.1172/JCI79434 (2016). [PubMed: 27525437]
57. Aspeland A et al. The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. *The Journal of clinical investigation* 124, 3975–3986, doi:10.1172/JCI75395 (2014). [PubMed: 25061878]
58. Maisel K et al. Immune Checkpoint Ligand PD-L1 is Upregulated in Pulmonary Lymphangiomyomatosis (LAM). *American journal of respiratory cell and molecular biology*, doi:10.1165/rcmb.2018-0123OC (2018).
59. Broggi MA, Schmalzer M, Lagarde N & Rossi SW Isolation of murine lymph node stromal cells. *Journal of visualized experiments : JoVE*, e51803, doi:10.3791/51803 (2014). [PubMed: 25178108]
60. Tong J et al. Fas-positive T cells regulate the resolution of airway inflammation in a murine model of asthma. *J Exp Med* 203, 1173–1184, doi:10.1084/jem.20051680 (2006). [PubMed: 16618792]
61. Lund AW et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. *Cell reports* 1, 191–199, doi:10.1016/j.celrep.2012.01.005 (2012). [PubMed: 22832193]




Figure 1: HDM-mediated allergic airway inflammation induces lymphangiogenesis during resolution and lymphangiogenesis can be blocked using anti-VEGFR-3 antibody treatment. (A) Schedule of HDM-induced allergic airway inflammation in mice. On day 0, 100 μ g HDM in 50 μ l PBS was given intranasally on day 0, followed by 4 challenges of 25 μ g each on days 7-10; after 8 weeks, 25 μ g HDM was given as a memory recall on day 66, followed by sacrifice on day 69. (B) Numbers of eosinophils (Ly-6G-CD11c^{lo}Siglec-F⁺, left) and Th2 (Foxp3⁻Gata3^{hi}) CD4⁺ T cells (right) in the lung throughout the acute, resolution, and memory recall phases. (C) VEGF-C and VEGF-D levels in the lungs using ELISA. (D) H&E staining showing inflammation and (E) VEGFR-3 immunofluorescence showing lymphatic vessels, comparing control (PBS-infused) with the three phases of HDM-induced inflammation. Scale bars, 500 μ m. (F) Quantification of lymphatic area (VEGFR-3⁺ pixels/DAPI⁺ pixels) in the lungs at these timepoints, as well as at day 31 using anti-VEGFR-3 mF4-31C1 (α R3). Boxes represent median (central bar) with range from 25th-75th percentile, and whiskers represent min to max value. Data is representative of n = 4 mice each in 2-3 experiments, and statistics (one-way ANOVA with Dunnett's Multiple Comparison Test) were performed in GraphPad Prism. * p<0.05.




Figure 2: VEGFR-3 blocking dampens acute HDM mediated inflammation in murine lungs and modulates dLN composition in the acute phase and during resolution.

(A) Schedule of HDM-induced allergic airway inflammation in mice. Mice were challenged with receiving 100 μ g HDM on day 0, followed by 4 consecutive challenges of 25 μ g of HDM on days 7-10. Pro-lymphangiogenic signaling was blocked using mF4-31C1 and mice were sacrificed to assess the level of inflammation either at day 13 (inflammatory peak) or at day 31 (final dose of mF4-31C1 given on day 21) in mice. (B) Overall CD45+ cells at day 13 and 31, with subsets including monocytes, neutrophils, B cells, alveolar macrophages, DCs, T cells, and eosinophils in the lungs. ($p < 0.05$: * - day 13, # - day 31). (C) Eosinophils, neutrophils, T cells, CD4+ T cells, and CD8+ T cells as %CD45+ cells at day 13 and 31. (D) CD4+ T cell subsets in lungs at day 13 and day 31, including T_{Reg} cells, Th2s, and T_{naive} cells as %CD4+ cells. All cell numbers were assessed via flow cytometry. Boxes represent median (central bar) with range from 25th-75th percentile, and whiskers represent min to max value. Data is representative of n = 4 mice and 2-3 experiments, and statistics (two-

tailed student's t test) were performed in GraphPad Prism. * or # $p < 0.05$, and $+ 0.05 < p < 0.1$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3: VEGFR-3 blocking treatment increases CD4+ T_{naive} in the dLN during acute inflammation and resolution, and decreases CCL21 and other chemokines in the lungs during acute inflammation.

Mice were challenged as described in Figure 2. CD4⁺ T cell subsets including CD4⁺ T_{naive}, T_{Reg} cells, and Th2s in the dLN at (A) day 13 and day 31. Levels of the CCR7 chemokine, CCL21, in lungs and dLN as determined by (B) immunofluorescence staining, possible since CCL21 both sticks to extracellular matrix and cytoplasm, (scale bar indicates 400 μm) and (C) ELISA. (D) Luminex assay on lung lysates to assess chemokine levels including CXCL2, CCL5, CCL7, CXCL10, CCL11, CCL12, CCL2, CXCL13, CCL3, and CXCL12 at

day 13. Boxes represent median (central bar) with range from 25th-75th percentile, and whiskers represent min to max value. Data is representative of n = 4 inflamed mice and statistics (two-tailed student's t test) were performed in GraphPad Prism. # 0.05 < p < 0.15, * p < 0.05, **p < 0.01, *** p < 0.001.




Figure 4: Blocking pro-lymphangiogenic signaling using the VEGFR-3 blocking antibody mF4-31C1 induces an exacerbated memory response to HDM.

(A) Schedule of HDM-induced allergic airway inflammation in mice (as described previously) including anti-VEGFR-3 blocking treatment using mF4-31C1. (B) Overall CD45⁺ inflammatory cell numbers. (C) Blinded inflammation score performed by a pathologist: perivascular inflammation and peribronchiolar inflammation was scored from 0-5 on an ordinal scale, with 0 indicating normal structures with no pathologic inflammatory cells, 1 indicating few scattered inflammatory cells, 2 indicating a circumferential inflammatory band 1 cell thick, 3 indicating a circumferential inflammatory band 2-4 cells thick, 4 indicating a circumferential inflammatory band >4 cells thick, and 5 indicating the presence of nodular lymphoid follicular hyperplasia. (D) Eosinophils, Th2 cells, and T_{Reg} cells levels as assessed by flow cytometry. (E) CD4⁺ T_{EM} to T_{CM} and Th2 to T_{Reg} ratios. (F) IL-4⁺ and IL-13⁺ CD4⁺ T cells levels after *in vitro* restimulation with PMA and ionomycin. (G) ELISAs for IL-4, -5, and -13 on HDM specific *in vitro* restimulated single cell lung lysate samples (48h). Boxes represent median (central bar) with range from 25th-75th percentile, and whiskers represent min to max value. Data is representative of n = 4 inflamed mice (n = 3 for PBS treated mice) and 2-3 experiments, and statistics (two tailed student's t test, comparing only HDM treated groups) were performed in GraphPad Prism. * p < 0.05, ** p < 0.01.




Figure 5: The exacerbated memory response is dependent on absence of both VEGF-C and VEGF-D.

(A) Schedule of HDM-induced allergic airway inflammation in mice including treatment of all mice with tamoxifen more than two weeks prior to inducing allergic inflammation. Allergic inflammation was induced in wild type ('WT') mice and mice lacking either VEGF-C (*Rosa26^{Cre-ERT2}; Vegfc^{flx/flx}*, here referred to as 'VC KO'), VEGF-D (*Vegfd^{-/-}*, here referred to as 'VD KO'), or both (*Rosa26^{Cre-ERT2}; Vegfc^{flx/flx}; Vegfd^{-/-}*, here referred to as 'double KO') that have been previously described^{33,34}. (B) H&E staining showing inflammation (scale bar indicates 500 μ m), and (C) blinded inflammation scores. Flow cytometric analysis of immune cell infiltration into the lungs including (D) eosinophils, (E) CD4+ T_{EM}/T_{CM} ratios, (F) T_{Reg} cells, and CD4+ Th2 cells, and (G) Th2/T_{Reg} ratios. (H-I) IL-5⁺, IL-13⁺, IFN γ ⁺, and IL5⁺13⁺ double producing CD4⁺ T cells after *in vitro* restimulation with PMA and ionomycin on lung single cell suspensions quantified via flow cytometry. (J) IL-4, IL-5, and IL-13 levels after 48h *in vitro* restimulation with HDM on lung single cell suspensions to assess antigen specificity of the Th2 cells in the lungs. Boxes represent median (central bar) with range from 25th-75th percentile, and whiskers represent min to max value. Data is representative of n = 4 mice for PBS treated and n = 6 mice for

inflamed mice (n = 1 experiment for mice lacking VCA/D), and statistics (one-way ANOVA with Dunnett's Multiple Comparison mice lacking VEGF-C and/or VEGF-D). Test) were performed in GraphPad Prism.* p<0.05, ** p = 0.01.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript